Category : Seeking Alpha

ETC’s Commercial/Industrial Unit Awarded Contracts Totaling $9.1 Million

SOUTHAMPTON, Pa., Nov. 07, 2025 (GLOBE NEWSWIRE) -- Environmental Tectonics Corporation’s (OTCID: ETCC) (“ETC” or the “Company”) Environmental Testing and Simulation Systems (“ETSS”) business unit announced it has been awarded a $7.0 million contra...

IO Biotech Presents Pre-Clinical Data Highlighting the Potential of Additional Therapeutic Cancer Vaccine Candidates at the 2025 Annual Meeting of the Society for Immunotherapy of Cancer (SITC)

IO Biotech Presents Pre-Clinical Data Highlighting the Potential of Additional Therapeutic Cancer Vaccine Candidates at the SITC 2025 Annual Meeting

MiNK Therapeutics Reports Durable Responses and Immune Reactivation with Allo-iNKT Cell Therapy agenT-797 in PD-1–Refractory Solid Tumors at SITC 2025

NEW YORK, Nov. 07, 2025 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering allogeneic invariant natural killer T (allo-iNKT) cell therapies to reconstitute immunity to treat cancer and...

BioAge Labs to Present at Jefferies Global Healthcare Conference in London

EMERYVILLE, Calif., Nov. 07, 2025 (GLOBE NEWSWIRE) -- BioAge Labs, Inc. (NASDAQ: BIOA) ("BioAge", "the Company"), a clinical-stage biotechnology company developing therapeutic product candidates for metabolic diseases by targeting the biology of hu...

Legrand Acquires Avtron Power Solutions, a Global Provider of Load Banks & Power Quality Solutions

WEST HARTFORD, Conn., Nov. 07, 2025 (GLOBE NEWSWIRE) -- Legrand®, a global leader in electrical and digital building infrastructures, announced that it has acquired Avtron Power Solutions, a leading global provider of load banks and power quality s...

NeOnc Technologies (Nasdaq: NTHI) to Host Investor Conference Call to Present Data Updates from Ongoing NEO100-1 Phase 1/2a Clinical Trial and Compassionate Use Program

CALABASAS, Calif., Nov. 07, 2025 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (NTHI) (“NeOnc” or the “Company”), a clinical-stage biopharmaceutical company developing novel brain-penetrant therapeutics for patients with malignant brain tum...

Coherus Oncology Presents at SITC Clinical Multiomic Biomarker Data for CHS-114, a Highly Selective anti-CCR8 Cytolytic Antibody

– CHS-114 demonstrated robust and selective depletion of CCR8+ Tregs as well as favorable immune remodeling in tumor tissue from head and neck squamous cell carcinoma (HNSCC) patients –

BioAtla’s Mecbotamab Vedotin (Mec-V), an AXL-targeting ADC, Demonstrates a Median Overall Survival (OS) of 21.5 months in Subtypes of Refractory Soft Tissue Sarcomas

— Mec-V demonstrates median OS of 21.5 months in patients with treatment-refractory leiomyosarcoma, liposarcoma, and undifferentiated pleomorphic sarcoma compared with approximately 12 months with approved agents

Precision Optics Announces Product Development Agreement to Deliver Next-Generation Augmented Reality Sub-Systems for Fighter Pilots

GARDNER, Mass., Nov. 07, 2025 (GLOBE NEWSWIRE) -- Precision Optics Corporation, Inc. (NASDAQ: POCI), a leading designer and manufacturer of advanced optical instruments for the medical and defense/aerospace industries, today announced the receipt o...

Wrap and LETAC Lead Policy Development for Human Centered Non-Lethal Integration of Humanoid Robotics in Public Safety

Partnership built to scale growing policy market and public demand to address future-state concerns around humanoid and robotic systems, recognizing ethical and operational demands and risks to help ensure non-lethal innovation Partnership built to s...

Draganfly to Host Shareholder Update Call on November 12, 2025

Saskatoon, SK, Nov. 07, 2025 (GLOBE NEWSWIRE) -- Draganfly Inc. (NASDAQ: DPRO; CSE: DPRO; FSE: 3U8A), an award-winning, industry-leading developer of drone solutions and systems, announced today that it will host a shareholder update call on Novemb...

Gold Prices Continue to Fluctuate at High Levels, Blue Hat's Gold Assets Deliver Significant Returns

NEW YORK, Nov. 07, 2025 (GLOBE NEWSWIRE) -- As of the reporting date, the price of gold futures on the New York Commodity Exchange continues to set historical all-time highs, reaching over $4,300 per ounce in October 2025, setting another historica...

NextNRG Reports Preliminary October 2025 Revenue Growth of 196% Year-Over-Year

MIAMI, FL, Nov. 07, 2025 (GLOBE NEWSWIRE) -- NextNRG, Inc. (NASDAQ:NXXT), a pioneer in AI-driven energy innovation transforming how energy is produced, managed, and delivered, today announced preliminary unaudited financial results for October 2025...

Nurix Therapeutics Presents New Translational Data from First-in-Human Clinical Trial of Oral CBL-B Inhibitor NX-1607 Demonstrating Immune Activation and Tumor Microenvironment Remodeling

New translational data supports potential of NX-1607 as a novel next generation checkpoint inhibitor therapy

Elicio Therapeutics Reports Robust, Cytolytic mKRAS-Specific T Cell Responses Across Diverse Patient HLA in Ongoing Phase 2 AMPLIFY-7P Trial of ELI-002 7P and New ELI-004 Preclinical Data at SITC

BOSTON, Nov. 07, 2025 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX, “Elicio” or the “Company”), a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer, today announced additi...